Tag: tumor microenvironment

Oncotarget News

Oncotarget

<img width="300" height="100" src="https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1-300x100.png" class="alignleft blogfeed wp-post-image" alt="Oncotarget" decoding="async" srcset="https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1-300x100.png 300w, https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1-1024x341.png 1024w, https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1-768x256.png 768w, https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1-1200x400.png 1200w, https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1.png 1500w" sizes="(max-width: 300px) 100vw, 300px" />

Cancer-Associated Fibroblasts: Challenges and Opportunities

April 5, 2023

Beyond detection of cancer, CAFs are being actively pursued as targets for therapy.” BUFFALO, NY- April 5, 2023 – A new editorial perspective was published in Oncotarget's Volume 14 on... read more

Oncotarget

<img width="300" height="100" src="https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1-300x100.png" class="alignleft blogfeed wp-post-image" alt="Oncotarget" decoding="async" srcset="https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1-300x100.png 300w, https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1-1024x341.png 1024w, https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1-768x256.png 768w, https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1-1200x400.png 1200w, https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1.png 1500w" sizes="(max-width: 300px) 100vw, 300px" />

Oncotarget | Myeloid-Derived Suppressor Cells: Cancer, Autoimmune Diseases, and More

November 29, 2022

MDSCs are heterogeneous immature myeloid cells that possess important actions in immune tolerance and tumor expansion.”BUFFALO, NY- November 29, 2022 – A new review was published in Oncotarget's Volume 13... read more

Dr. Robert Hsu

Behind the Study: Molecular Characterization of Lung Carcinomas Expressing KK-LC-1

July 11, 2022

Dr. Robert Hsu from the University of Southern California, Norris Comprehensive Cancer Center, describes a recent research paper he co-authored that was published by Oncotarget, entitled, “Molecular characterization of... read more